PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsZaleplon
Sonata(zaleplon)
Sonata, Zaleplon, Zerene (zaleplon) is a small molecule pharmaceutical. Zaleplon was first approved as Sonata on 1999-03-12. It is used to treat sleep initiation and maintenance disorders in the USA. It has been approved in Europe to treat sleep initiation and maintenance disorders.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
Zaleplon (discontinued: Sonata, Zaleplon)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Zaleplon
Tradename
Company
Number
Date
Products
SONATAPfizerN-020859 DISCN1999-08-13
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
sonataNew Drug Application2010-05-27
zaleplonANDA2025-10-17
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
sleep initiation and maintenance disorders—D007319F51.01
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05C: Hypnotics and sedatives
— N05CF: Benzodiazepine related hypnotics and sedatives
— N05CF03: Zaleplon
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameZaleplon
INNzaleplon
Description
Zaleplon is a pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position. It has a role as an anticonvulsant, a central nervous system depressant, a sedative and an anxiolytic drug. It is a pyrazolopyrimidine and a nitrile.
Classification
Small molecule
Drug classnon-benzodiazepine anxiolytics, sedatives, hypnotics
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
Identifiers
PDB—
CAS-ID151319-34-5
RxCUI—
ChEMBL IDCHEMBL1521
ChEBI ID10102
PubChem CID5719
DrugBankDB00962
UNII IDS62U433RMH (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Zaleplon
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,566 documents
View more details
Safety
Black-box Warning
Black-box warning for: Zaleplon
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
856 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use